Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
47.83
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
40
41
Next >
Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket
↗
August 17, 2022
Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.
Via
Benzinga
Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus
↗
August 12, 2022
New York officials have detected polio in the city's wastewater, suggesting the virus has been circulating in the local area.
Via
Benzinga
Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
↗
August 11, 2022
Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
August 11, 2022
On Thursday, 22 companies reached new 52-week lows.
Via
Benzinga
Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
↗
August 04, 2022
Via
Benzinga
Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain
↗
July 28, 2022
The company reported more than 40% growth for Dupixent in the second quarter.
Via
Investor's Business Daily
GSK, PFE, SNY Stocks Fall on Zantac Litigation
↗
August 11, 2022
You may think safety concerns about Zantac from 2019 are old news now, but GSK stock traders and others are worried about the repercussions.
Via
InvestorPlace
Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms
↗
August 11, 2022
These companies are at the center of lawsuits claiming Zantac causes cancer.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
August 11, 2022
Via
Benzinga
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
↗
August 11, 2022
Gainers
Via
Benzinga
Sanofi Raises Annual Guidance On Upbeat Q2 Performance
↗
July 28, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
August 11, 2022
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch!
Via
InvestorPlace
Sonos, Bumble And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
↗
August 11, 2022
Via
Benzinga
WeTrade, Roblox And Some Other Big Stocks Moving Lower On Wednesday
↗
August 10, 2022
OptimizeRx Corporation (NASDAQ: OPRX) shares fell 26.7% to $16.32 after the company reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
August 10, 2022
During Wednesday, 52 stocks hit new 52-week lows.
Via
Benzinga
Sanofi (NASDAQ:SNY) Shareholder Notice: Investigation Concerning Possible Violations of Securities Laws
↗
August 09, 2022
San Diego, CA -- (SBWIRE) -- 08/09/2022 -- Sanofi is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Monkeypox Plays Jockey For Position This Week
August 08, 2022
Via
AB Newswire
Looking Into Sanofi's Recent Short Interest
↗
August 04, 2022
Sanofi's (NASDAQ:SNY) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 2.31 million shares sold short, which is 0.09% of...
Via
Benzinga
How Siga Is Turning Its Biowarfare Soldier Onto This Outbreak ... And The Next
↗
August 04, 2022
Siga stock more than tripled, emerging from under the radar to take on the outbreak.
Via
Investor's Business Daily
Regeneron's Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
↗
August 03, 2022
Via
Benzinga
A Bearish Sign Appears On Sanofi's Chart
↗
August 03, 2022
If history is any guide, there may be trouble ahead for shares of Sanofi (NASDAQ:SNY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
↗
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
3-D Portfolio: Discounts, Diversification, And Dividends
↗
July 31, 2022
When it comes to high-yield closed-end funds, I’m a big fan of the “three Ds” — discounts, diversification, and dividends. Today, we’ll look at a three-fund, bargain-priced “3-D” CEF portfolio you can...
Via
Talk Markets
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
↗
July 30, 2022
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...
Via
Talk Markets
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
↗
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
↗
July 28, 2022
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, received an AU$1 million (US$694,000) gran
Via
Benzinga
Earnings Scheduled For July 28, 2022
↗
July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter.
Via
Benzinga
Earnings Outlook For Sanofi
↗
July 27, 2022
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an...
Via
Benzinga
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
↗
July 25, 2022
Via
Benzinga
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
↗
July 25, 2022
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
40
41
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.